Active, Not Recruiting
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
NCT02185560
- Conditions
- Endocrine Gland Neoplasms, Endocrine System Diseases, Head and Neck Neoplasms, +5 more
- Locations
-
- Multiple Locations, Japan